cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Myriad Genetics Inc
2 own
6 watching
Current Price
$19.72
$0.46
(2.39%)
logo-mygn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,595.35M
52-Week High
52-Week High
28.18
52-Week Low
52-Week Low
13.92
Average Volume
Average Volume
0.67M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
22.73
iconMarket Capitalization1,595.35M
icon52-Week High28.18
icon52-Week Low13.92
iconAverage Volume0.67M
iconDividend Yield--
iconP/E Ratio22.73
What does the Myriad Genetics Inc do?
Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease; identify a patient's likelihood of responding to drug therapy; guide a patient's dosing to ensure optimal treatment; and assess a patient's risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS test for colorectal and uterine cancers; COLARIS AP test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for prostate cancer; EndoPredict RNA expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; myChoice homologous recombination deficiency (HRD) test to measure three modes of HRD; and myPlan lung cancer, an RNA expression test for lung cancer. Myriad Genetics, Inc. has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
How much money does Myriad Genetics Inc make?
News & Events about Myriad Genetics Inc.
Globe Newswire
27days ago
Myriad Genetics continues to advance non-invasive prenatal screening with Prequel and the forthcoming FirstGene test using AMPLIFY technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced ...
Globe Newswire
28days ago
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (...
Globe Newswire
1month ago
Myriads MyRisk Hereditary Cancer test with RiskScore provides a personalized breast cancer risk assessment for women of all ancestriesSALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.(NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results ...
Globe Newswire
3 months ago
$67.5 million tuck-in acquisition strengthens Myriads Womens Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents learn babys gender from home earliest method to date at 6 weeks into pregnancy SALT LAKE CITY, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, ...
Globe Newswire
3 months ago
Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates1 ($5.3 million). Third quarter testing volumes, excluding divested businesses, grew 12% year...
Frequently Asked Questions
Frequently Asked Questions
What is Myriad Genetics Inc share price today?
plus_minus_icon
Can Indians buy Myriad Genetics Inc shares?
plus_minus_icon
How can I buy Myriad Genetics Inc shares from India?
plus_minus_icon
Can Fractional shares of Myriad Genetics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Myriad Genetics Inc stocks?
plus_minus_icon
What is today’s traded volume of Myriad Genetics Inc?
plus_minus_icon
What is today’s market capitalisation of Myriad Genetics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Myriad Genetics Inc?
plus_minus_icon
What percentage is Myriad Genetics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Myriad Genetics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$19.72
$0.46
(2.39%)
logo-mygn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Syneos Health, Inc.
Syneos Health, Inc.
$35.92
$0.62 (1.76 %)
Bloomin' Brands, Inc.
Bloomin' Brands, Inc.
$24.25
$0.60 (2.54 %)
United Continental Holdings, Inc.
United Continental Holdings, Inc.
$48.96
$0.75 (1.56 %)
Nordstrom Inc.
Nordstrom Inc.
$19.54
$0.76 (4.05 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Syneos Health, Inc.
Syneos Health, Inc.
$35.92
$0.62 (1.76 %)
Bloomin' Brands, Inc.
Bloomin' Brands, Inc.
$24.25
$0.60 (2.54 %)
United Continental Holdings, Inc.
United Continental Holdings, Inc.
$48.96
$0.75 (1.56 %)
Nordstrom Inc.
Nordstrom Inc.
$19.54
$0.76 (4.05 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00